Skip to main content
Open Access Publications from the University of California

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib

  • Author(s): Jones, JA
  • Hillmen, P
  • Coutre, S
  • Tam, C
  • Furman, RR
  • Barr, PM
  • Schuster, SJ
  • Kipps, TJ
  • Flinn, IW
  • Jaeger, U
  • Burger, JA
  • Cheng, M
  • Ninomoto, J
  • James, DF
  • Byrd, JC
  • O'Brien, SM
  • et al.

Published Web Location Commons Attribution 4.0 International Public License

© 2017 John Wiley & Sons Ltd Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View